Endogenous neogenesis of beta cells
First Claim
1. A method of producing pancreatic beta cells in a subject, comprisingadministering to the subject a vector comprising a glucagon promoter operably linked to a nucleic acid sequence encoding heterologous Pancreas duodenal homeobox protein (Pdx) 1 and a nucleic acid sequence encoding Musculoaponeurotic fibrosarcoma oncogene homolog A (MafA), wherein the vector does not encode Neurogenin 3 (Ngn3), wherein the subject is not administered any other nucleic acid encoding Ngn3, wherein the glucagon promoter a) consists of the nucleic acid sequence of SEQ ID NO:
- 1, or b) comprises the nucleic acid sequence of SEQ ID NO;
3, and wherein the vector is administered intraductally into a pancreatic duct of the subject,thereby inducing alpha cells to transform into pancreatic beta cells in the subject.
2 Assignments
0 Petitions
Accused Products
Abstract
Methods are disclosed for producing pancreatic beta cells in a subject. The methods include administering to the subject a vector encoding heterologous Pancreas duodenal homeobox protein (Pdx) 1 and MafA, wherein the vector does not encode Neurogenin 3 (Ngn3) and wherein the subject is not administered any other nucleic acid encoding Ngn3. The vector is administered intraductally into a pancreatic duct of the subject. Compositions are disclosed that include a) a viral vector comprising a promoter operably linked to a nucleic acids encoding Pdx1 and a nucleic acid encoding MafA, wherein the vector does not encode Ngn3; b) a buffer; and c) a contrast dye for endoscopic retrograde cholangiopancreatography. These compositions are of use in any of the methods disclosed herein.
-
Citations
22 Claims
-
1. A method of producing pancreatic beta cells in a subject, comprising
administering to the subject a vector comprising a glucagon promoter operably linked to a nucleic acid sequence encoding heterologous Pancreas duodenal homeobox protein (Pdx) 1 and a nucleic acid sequence encoding Musculoaponeurotic fibrosarcoma oncogene homolog A (MafA), wherein the vector does not encode Neurogenin 3 (Ngn3), wherein the subject is not administered any other nucleic acid encoding Ngn3, wherein the glucagon promoter a) consists of the nucleic acid sequence of SEQ ID NO: - 1, or b) comprises the nucleic acid sequence of SEQ ID NO;
3, and wherein the vector is administered intraductally into a pancreatic duct of the subject,thereby inducing alpha cells to transform into pancreatic beta cells in the subject. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
- 1, or b) comprises the nucleic acid sequence of SEQ ID NO;
-
13. A composition comprising:
-
a) an adeno-associated virus vector comprising a glucagon promoter operably linked to a nucleic acid sequence encoding Pdx1 and a nucleic acid sequence encoding MafA, wherein the vector does not encode Neurogenin 3 (Ngn3), and wherein the glucagon promoter a) consists of the nucleic acid sequence of SEQ ID NO;
1, or b) comprises the nucleic acid sequence of SEQ ID NO;
3;b) a buffer; and c) a contrast dye for endoscopic retrograde cholangiopancreatography. - View Dependent Claims (14, 15, 16, 17, 18, 19, 20, 21, 22)
-
Specification